AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 µM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent[1].
Molekulargewicht:
280.35
CAS Nummer:
[226717-28-8]
Formel:
C15H12N4S
Target-Kategorie:
FLT3,PDGFR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
